Camp4 Therapeutics, a Cambridge, MA-based platform to discover effective treatment approaches for every disease, raised $30M in Series A financing.
The round was led by Andreessen Horowitz, with participation from Polaris Partners and The Kraft Group.
The company intends to use the funds to expand its development efforts.
Co-founded in 2016 by Dr. Richard Young (Whitehead Institute/MIT) and Dr. Leonard Zon (Boston Children’s Hospital/Harvard University) and led by Josh Mandel-Brehm, CEO, Camp4 Therapeutics has created a Gene Circuitry Platform to amplify the value of cellular and genetic insights to better understand how genes are controlled by signaling pathways in specific disease states. By generating proprietary 4D maps, the pltform can identify de-risked druggable targets, produce actionable insights and improve therapeutic predictability, potentially addressing hundreds of diseases and benefiting millions of patients globally.